65043-22-3

Indeloxazine hydrochloride is a nootropic indicated for the treatment of senile dementia. In animal models indeloxazine reportedly enhances brain energy metabolism and monoamine content; its claimed protective effect on ischemia-induced amnesia is supported by the prolonged step-through latency in passive avoidance tests.

Polymorphic Forms: Pale yellow needle-shaped crystals obtained from methanol, melting point 169-170°C; colorless acicular crystals obtained from acetone, melting point 155-156°C. Acute toxicity LD50 in mice (mg/kg): 47 mg/kg by intravenous injection. (+)-Form: Crystals obtained from ethanol, melting point 112-113°C. [α]D21 + 4.9° (C = 5, methanol). (-)-Form: Crystals obtained from isopropanol, melting point 142-142.5°C. [α]D20 - 4.9° (C = 5, methanol).

Yamanouchi (Japan)

Antidepressant.

Elen

After oral administration of indeloxazine hydrochloride to rats, two conjugates, which are labile to a- glucosidase hydrolysis but refractory to b-glucosidase, are isolated from the urine and identified as a-D- glucopyranosides of trans-4-(2-morpholinylmethoxy)- 1,2-indandiol and trans-6-[[(1,2-dihydroxy-4- indanyl)oxy]-methyl]-3-morpholinone.